Miracle Mile Advisors LLC Buys 25,117 Shares of Gilead Sciences, Inc. $GILD

Miracle Mile Advisors LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 279.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,104 shares of the biopharmaceutical company’s stock after buying an additional 25,117 shares during the period. Miracle Mile Advisors LLC’s holdings in Gilead Sciences were worth $3,786,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. GoalVest Advisory LLC increased its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the 2nd quarter valued at $27,000. Putney Financial Group LLC increased its stake in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter worth $30,000. Finally, Kilter Group LLC acquired a new position in Gilead Sciences during the second quarter worth $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. HSBC raised their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Truist Financial started coverage on Gilead Sciences in a research report on Monday, November 24th. They set a “buy” rating and a $140.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Daiwa Capital Markets raised their price objective on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Finally, Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $131.68.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total value of $366,000.00. Following the sale, the chief financial officer directly owned 153,503 shares in the company, valued at $18,727,366. The trade was a 1.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 136,257 shares of company stock worth $16,855,192 in the last three months. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Down 0.4%

GILD stock opened at $122.74 on Friday. The stock has a market cap of $152.28 billion, a P/E ratio of 19.03, a P/E/G ratio of 0.68 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock’s fifty day simple moving average is $123.04 and its two-hundred day simple moving average is $116.97. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.